Funding Digital Therapeutics – Who counts?

Digital therapeutics, when created empathetically to patients and health care professionals (HCPs), can show significant value to all stakeholders in the healthcare pathway [1]. A question at a recent NHS conference prompted an important question: if pharma is funding these innovations with a commercial motivation, how do you ensure equality in access to digital therapeutics?…